Are all antidepressants alike? by Schulz, Pierre
Antidepressants are indicated in about 40 different
disorders, including mood disorders, anxiety disor-
ders, and other disorders. We propose to call these
disorders antidepressant-responsive disorders
(ARDs). We describe the clinical and biological cri-
teria that differentiate the antidepressants.
Although antidepressants share the same clinical
efficacy in most ARDs, the configuration of adverse
drug reactions varies widely. The recent antide-
pressants should be preferred to the tricyclic anti-
depressants as first-line treatment because of their
lesser risk of severe adverse drug reactions. How-
ever, several recent antidepressants have been
associated with severe complications such as the
serotonin syndrome and the withdrawal syndrome.
Patient characteristics should be included as a cri-
terion to predict both unwanted and favorable
effects. 
Mood and antidepressants
lthough the symptoms and signs of depressive
states are well described, the physiology of normal mood
remains quite mysterious. Mood is the integration over time
of the emotions that accompany our representation of our
present and future situation in this world. However, mood is
not just the resultant of this representation, it can also influ-
ence the representation. Figure 1 shows an engraving by the
French painter Le Brun, a protégé of King Louis XIV. Le
Brun was interested in the ways people expressed their feel-
ings and emotions and produced numerous portraits on this
theme. To accompany his depiction of extreme despair, he
wrote his definition of severe depression (our translation):
“Despair stems from the belief that we are not getting what
we long for, and has the consequence that we lose even what
we have got.” Typifying a totally opposite expression of
mood, the contemporary American artist Jenny Holzer once
wrote: “In a dream, you saw a way to survive and you were
full of joy.”  These artists, and many others, reflected in their
works their understanding of the interactions between cog-
nition and emotion in the construct of human thinking. In
simpler terms, we may state that every sentient being has
two major goals: to experience pleasure and avoid pain.
Mood can be viewed as an indicator of the success in achiev-
ing these goals. But mood is a composite higher brain func-
tion; it includes memory, programming, primary and sec-
ondary emotions, as well as a huge array of beliefs
concerning the physical and psychological worlds. 
The main characteristic of psychotropic drugs is that they
influence higher brain functions; by doing so, they also
improve the symptoms and signs of psychiatric disorders.
Like all other pharmacological agents, psychotropics exert
their beneficial effects by inducing a disequilibrium in
physiological systems. However, this disequilibrium proves
to be useful because the system was not functioning prop-
erly to start with. Antidepressants (ADs) are medications
that modify mood, in the same manner as diuretics are
medications that modify the circulating blood compart-
ment. While the links between arterial hypertension and the
physiology of the circulating blood compartment (elec-
trolyte metabolism, vascular muscle tone, cardiac output,
and mental stress) are well understood, the same cannot be
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mood.  ADs are useful in many disorders that are not clas-
sified as mood disorders; in fact, there are more than 40
different antidepressant-responsive disorders (ARDs). This
can be explained in part by taking into account the fact that
many higher brain functions are involved in the composite
concept of mood, and that these functions can be altered in
other psychiatric disorders as well. Anxiety disorders, one
of the categories of ARDs, could be viewed as disorders of
the normal function of anticipation of the future or of
detection of danger. Obsessive-compulsive disorder
appears to be a disorder where the safety of successive con-
ditions and of the consequences of one’s behaviors cannot
be recognized by the subject. These introductory remarks
illustrate that ADs are medications that act on higher brain
functions, ie, they exert a pharmacological action on the
highly abstract functions that enable us to construct multi-
modal representations of the world and adapt our behavior.
Criteria for the classification 
of antidepressants
Many criteria can be used to classify and compare ADs.
These are summarized in Table I. Some degree of overlap
can exist between these criteria.
ADs are medications for the treatment of mood disorders.
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This truism is more complex than appears at first glance.
Indeed, there are more than 20 different types of depressive
disorders, such as major depressive episode with melan-
cholic features, seasonal features, or postpartum onset, pre-
menstrual dysphoric disorder, brief recurrent depressive dis-
order, depression in bipolar mood disorder, depression due to
an endocrine or other general medical condition. Anxiety
disorders should be added to the list of ARDs, because these
disorders respond to the more recent ADs. ADs are also indi-
cated in bulimia nervosa, conduct disorders in mental defi-
ciency or dementia, depression in schizophrenia, fibromyal-
gia, enuresis, and other disorders. 
In view of the multitude of ADs and of their indications, we
propose to coin the word “disorderogram,” and distinguish
two types thereof: those centered on a disorder and those
centered on an AD. Disorder-centered disorderograms look at
the comparative efficacy of ADs in the management (treat-
ment of acute manifestations and prevention of relapses) of
a given disorder, whereas AD-centered disorderograms look
at the efficacy of a given AD with respect to the whole range
of its indications (all ARDs). The total number of disordero-
grams is high, around 40 for the disorder-centered disor-
derograms and around 25 for the AD-centered ones (there are
25 ADs currently available on the Swiss market). Such a
large amount of information makes it extremely difficult to
make an exhaustive comparison between the different ADs.
In the following, we will discuss the general aspects of the
efficacy of ADs.
Clinical efficacy of antidepressants
Positive aspects of antidepressants in general
All molecules that meet the definition of ADs have the capac-
ity to change in a radical and positive way the life of subjects
suffering from mood disorders. Prevention of relapses and
prevention of suicide attempts are also positive characteris-
tics that are common to all ADs. When the aim is not to treat
an acute depressive episode, but to suppress long-lasting suf-
fering related to panic attacks, dysthymia, or phobias, the new
ADs have the advantage, because they have been studied
more extensively in
these indications, and
because of their less-
er risk of severe
adverse drug reac-
tions. Comorbidity is
frequent, for exam-
ple, in cases where
dysthymia or chronic
depression is thought
to originate in social
isolation resulting
from social phobia
or an avoidant per-
sonality disorder.
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Figure 1. Depiction of despair according to Le Brun. Le Brun was a
painter at the time of the French king Louis XIV. See text for
his definition of despair. Table I. Criteria for the comparison of antidepressants.
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CostsNegative aspects of antidepressants in general 
The efficacy of ADs in depressive mood disorders develops
only after a delay of a few days to 4 weeks. Despite hopes
and promises, no AD has been demonstrated to have a
quicker onset of antidepressant efficacy. An average of 20%
to 40% of patients with major depression do not respond to
therapy, and there is no proof that any given drug is more
efficacious than any other. The debate over clinical efficacy
in the difficult-to-treat cases of severe depression or depres-
sion with melancholic or psychotic characteristics is still
unresolved, with some publications indicating superiority of
tricyclic antidepressants (TCAs),
2 while other studies or
meta-analyses
3 report recent ADs to have equal efficacy.
Comparison of studies is complicated by the fact that the
rate of drug response varies between studies, from low val-
ues, in the order of 30%, to very high values of 70% or more.
In some studies where TCAs were found to have greater
efficacy than recent ADs, the dosage of the latter may have
been too low. The issue of clinical superiority of a given AD
in other ARDs is also complex, with the exception that ADs
that influence the serotoninergic system are more efficacious
in obsessive-compulsive disorder than those acting selec-
tively on noradrenergic systems.
Adverse drug reactions
This criterion of comparison between ADs is the one most
relevant to clinical practice, since the differences in efficacy
between ADs are so minimal. 
Positive aspects of recent antidepressants
Recent ADs show less frequent and less severe adverse drug
reactions. With a classic TCAsuch as amitriptyline, admin-
istration of a daily dosage of 100 to 200 mg will induce
sedation, dry mouth, constipation, hypotension, impairment
of psychomotor performance (choice reaction time or criti-
cal flicker/fusion frequency) persisting even when the sub-
jective feeling of sedation has worn off, intracardiac con-
duction disturbances, and risk of convulsions. These adverse
reactions are the reason why the dosage of TCAs has to be
achieved progressively, over several days. Because of these
adverse reactions, the patient may have to stay off work for
longer periods of time with TCAs than with recent ADs.
These drugs may also induce weight gain of over 10 kg in
several weeks and impaired sexual function, which are a
source of distress to patients. Altough the adverse reactions
of recent ADs may occasionally be experienced by patients
as disagreeable and troublesome, they are less frequent and
less severe than those of the TCAs. This advantage is borne
out by some patients treated with recent ADs who report
no medication-related unwanted effects, a degree of patient
satisfaction paralleled only rarely by the TCAs. 
Further confirmation comes from clinical trials indicating a
patient dropout rate of ≥15% with recent ADs compared to
≥20 % with TCAs, and clinical practice data based on 13
619 prescriptions, which showed dropout rates of 22% and
33%, respectively.
4 Mortality after suicide attempts is almost
nonexistent with the newer ADs, while it was between 0.5%
and 4% of patients who were hospitalized after a failed sui-
cide attempt in cases of TCAoverdose. 
Negative aspects of recent antidepressants
The adverse drug reactions observed with recent ADs include
tremor, nausea, diarrhea, vertigo, sweating, headache,
impaired sexual function, sleep fragmentation, anxiety, ner-
vousness, akathisia (inability to remain in sitting posture,
restlessness, muscular quivering, anxiety, irritability), iatro-
genic mania, withdrawal symptoms, and the serotonin syn-
drome. These adverse drug reactions do not occur with all the
recent ADs. For example, sedation is typical of nefazodone
and mirtazapine, and these ADs also induce dry mouth. Nefa-
zodone does not induce sleep fragmentation, in contrast to
the selective serotonin reuptake inhibitors (SSRIs).
5 Mir-
tazapine causes weight gain, in contrast to most of the newer
ADs like the SSRIs and venlafaxine, which induce a loss of
appetite and an increase in whole body metabolism, usually
resulting in little weight change, although some patients may
lose or gain weight because of the treatment.
Among the recent ADs, fluoxetine, sertraline, moclobemide,
and bupropion are the less sedating molecules, the first two
even increase choice reaction time in normal volunteers. Sex-
ual adverse reactions, when they occur, are generally a minor
problem for the patient during the acute phase of the treat-
ment of a depressive disorder, but they are bothersome during
the maintenance phase. The SSRIs (with the possible excep-
tion of fluvoxamine) are associated with a higher incidence of
sexual dysfunction than nefazodone, moclobemide, or mir-
tazapine. Bupropion, which influences the dopaminergic sys-
tem, can activate the libido.
Recent ADs can induce hypomania or mania in some sub-
jects, a phenomenon referred to as the “iatrogenic switch.”
This may also occur with TCAs and some nonpharmacolog-
ical therapies such as sleep deprivation or electroconvulsive
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respect, but this needs confirmation. Overall, as many as
about one fifth of bipolar I patients develop iatrogenic hypo-
mania or mania during treatment for a depressive episode.
However, the exact relation between ADs and the “iatro-
genic switch” is controversial, because bipolar mood disor-
ders have such a high rate of recurrence anyway. There is
also a minor form of AD-induced euphoria that would not
qualify for hypomania or mania according to the judgement
of most clinicians, in which, for example, the patient comes
to the consultation saying that he or she feels really well and
has no more problems. This wonderful improvement should
alert the clinician to a possible loss of empathy or neglect of
justified preoccupations. Indeed, such patients may stop wor-
rying about their children’s education, blithely stating that
they are not gifted enough to continue studies, or may fail to
undertake the necessary steps to address a difficult profes-
sional situation. One patient, known previously to be much
preoccupied about environmental issues, found that global
warming was no longer a matter of concern to him. Such
“subsyndromic” forms of mania may be either an adverse
drug reaction seen with the newer ADs, or a behavioral
change resulting from patients enjoying a psychological bal-
ance they had been unable to achieve for years or even
decades. The differential diagnosis can be difficult. Aminor-
ity of activists in the United States contend that the effects of
the SSRIs, in particular fluoxetine, on the mental state of
patients are similar to those experienced by Sigmund Freud
when he started taking cocaine, or those induced by the
amphetamines, when their supposed merits in the treatment
of depression or fatigue were much vaunted 50 years ago. A
detailed literature search carried out by us disclosed no evi-
dence of addictive potential with either the old or the recent
ADs, with the possible exception of the nonselective irre-
versible monoamine oxidase inhibitors (MAOIs) or the
dopaminergic antidepressants, for which a very low risk may
exist in some predisposed subjects. ADs, therefore, do not
appear to be addictive: for example, drug addicts who are
capable of recognizing psychostimulants or benzodiazepines,
fail to discriminate between sertraline and placebo.
6 The rare
cases of addiction to ADs concern subjects who were previ-
ously addicted to many other substances. Furthermore, recent
ADs have been prescribed to psychostimulant addicts and
other addicts, with a somewhat debatable rate of success,
but certainly without the occurrence of massive and frequent
addiction. 
The serotonin syndrome is a severe adverse drug reaction
7
characterized by a wide range of manifestations including
diarrhea, profuse sweating (diaphoresis), anxiety, agitation,
hypomania, tremor, myoclonia, hyperreflexia, impaired vig-
ilance, etc. Distinction between the above and the neurolep-
tic malignant syndrome may be difficult in case of occur-
rence of hyperthermia, muscular rigidity, and increase in
creatine phosphokinase enzymes (CPK). Severe serotonin
syndromes have not been frequently described with TCAs, in
spite of the fact that these ADs also inhibit the presynaptic
serotonin transporter. One explanation for this may be that
the other adverse reactions of TCAs make it impossible to
increase their dosage to the point where a severe serotonin
syndrome would become manifest. 
The withdrawal syndrome of SSRIs and other ADs acting on
the serotoninergic system includes nausea, diarrhea, abdom-
inal cramps, anxiety, vertigo, feelings of electric discharges,
muscle pains, and flu-like syndromes.
8 Insomnia, night-
mares, hypnagogic hallucinations, irritability, hypomania,
and mood lowering have also been described. It is to be
noted that several of these manifestations are also those of
the serotonin syndrome, which can complicate the diagno-
sis. Withdrawal symptoms have also been described after
stopping TCA or MAOI treatment.
9,10 and, in the case of
TCAs, have been attributed in part to a cholinergic rebound
added to the reversal of presynaptic serotonin transporter
inhibition. Paroxetine is the recent AD most often cited 
in relation to the withdrawal syndrome, perhaps due to 
the fact that it has an anticholinergic action and is a power-
ful inhibitor of the serotonin transporter. Venlafaxine also
induces withdrawal syndromes, because of its short elimi-
nation half-life. Fluoxetine, probably because of its long
half-life, is associated with a very low risk of withdrawal
syndrome. In all cases, when the diagnosis of AD withdraw-
al is made, the best approach is to reinstate the AD treatment
and schedule a slower decrease in dosage.
Mode of action
The mode of action of a psychotropic medication can be
analyzed at several levels, from the macroscopic to the bio-
chemical. 
Psychological mode of action
An important problem is to determine the specificities of the
psychological mode of action of ADs, in other words, to
determine which ones are more effective, eg, in improving
the capacity to experience pleasurable events or in reducing
the tendency to perceive only the potential dangers or nega-
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7tive aspects of life, and which ones appear to enhance the
ability to engage in rewarding social relationships, or
improve cognitive impairment or vigilance and attention. In
our opinion, most or all of the above effects contribute to the
antidepressant effects of ADs, but there are very few studies
investigating how ADs modify the different higher brain
functions mentioned above, although such studies would be
very useful, if only because of the implications in terms of
how ADs are marketed. Reboxetine is a case in point. Rebox-
etine was found to have no greater anxiolytic or antidepres-
sant efficacy than fluoxetine in several comparative trials, but
when a scale for the self-evaluation of social adaptation was
applied, this selective inhibitor of the norepinephrine presyn-
aptic transporter was found to be superior to fluoxetine.
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Howevever, this difference will have to be confirmed before
too many hypotheses are made about the respective roles of
serotonin and norepinephrine in social functioning!
Another aspect is how ADs are characterized in terms of
adverse drug reactions. Some ADs are sedative, others are
stimulating; most can induce anxiety during the first days of
treatment (and this is a reason to use low doses of SSRIs dur-
ing the first days of treatment of anxiety disorders). 
Neurophysiological mode of action
ADs influence the serotoninergic, noradrenergic, and
dopaminergic systems. These systems act through mass trans-
fer of information: this means that they act little via point-to-
point synapses, but rather influence segments of other brain
areas in a global manner through the release of neurotrans-
mitters in the interstitial fluid. Examples of major groups of
cells or nuclei that contain these neurotransmitters are the
locus ceruleus for norepinephrine, the raphe nuclei for sero-
tonin, and the nucleus accumbens for dopamine. These nuclei
are focal points for responses to the environment and for con-
structing behaviors. For example, a dog taken into a certain
room and given good food will show activation of the nucleus
accumbens cells. If, the next day, it is taken into the same
room, it will show this activation of the nucleus accumbens
even before food is given. This indicates that the nucleus
accumbens is activated in pleasurable conditions as well as in
anticipation of these conditions. The neurophysiology of these
major nuclei during chronic treatment with ADs has not been
sufficiently studied to get a clear picture of the influence of
treatment on the neuronal activity level during chronic AD
treatment and under different conditions (baseline, moderate
stress, etc). Another approach to gaining a better understand-
ing of the mode of action of ADs is to study specific aspects
of their psychophysiological effects, such as the influence on
sleep architecture. For example, the fact that rapid eye move-
ment (REM) sleep is inhibited by many ADs as well as by
sleep deprivation has been taken as an indication that REM
sleep inhibition had inherent antidepressant effects; this is,
however, still an hypothesis in view of the fact that some
recent ADs do not influence sleep architecture.
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Biochemical mode of action
The biochemistry of neurotransmitter release and uptake in
the synapse includes the following major steps. A series of
precursor molecules are synthesized, the neurotransmitter is
stored in intracellular vesicles, which then release it into the
synaptic cleft. A presynaptic membrane protein serves as
transporter for the neurotransmitter, ensuring its reuptake,
and this reuptake is the main level where the influence of the
neurotransmitter on the postsynaptic receptors can be inhib-
ited. Some presynaptic receptors exert an inhibitory effect on
neurotransmitter release when activated by the neurotrans-
mitter. Finally, at the postsynaptic level, a cascade of events
follows the binding of neurotransmitters or other ligands to
the membrane receptors. This leads to changes in cytoplas-
mic chemical signaling systems and subsequent synthesis of
new peptides. ADs, like other psychotropic medications or
addictive drugs, can act at any of these biochemical steps,
and each AD has a distinctive “enzymogram,” “receptoro-
gram,” and “transporterogram.” These configurations of bio-
chemical or pharmacological modes of action are well
described in the literature. A TCA such as amitriptyline
inhibits the serotonin and norepinephrine transporters, and
this probably explains its antidepressant effects. Amitripty-
line also antagonizes the cholinergic muscarinic receptors
(all types), the histaminergic H1 and H2 receptors, the 5-HT2
receptor, and the α 1-adrenergic receptor. It slows down
intracardiac electrical conduction and inhibits prostaglandin
synthesis. These multiple actions explain why amitriptyline
can improve duodenal ulcer, lower arterial hypertension, pre-
vent recurrent migraine, and improve ventricular extrasys-
toles, pruriginous skin disorders, nocturnal enuresis, and pre-
mature ejaculation. These clinical effects can all be explained
on the basis of the “enzymogram,” “receptorogram,” and
“transporterogram” of amitriptyline, rather than by psycho-
somatic theories. Amitriptyline has been shown to be effec-
tive even after cutaneous application in cases of pruriginous
dermatitis, thus providing a strong argument against the idea
that ADs improve the symptoms of these disorders through a
central action on so-called masked depression. Compared to
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“enzymograms,” “receptorograms,” and “transportero-
grams,” despite their having more than a single mode of
action. While all SSRIs antagonize the serotonin transporter,
fluoxetine also inhibits the 2D6 cytochrome P450 enzymes
and possibly also peripheral and central cholinergic and nico-
tinic receptors, as well as 5-HT2C receptors. Sertraline may
act on dopamine and on sigma systems. 
ADs also influence neuroendocrine systems. For example,
some TCAs inhibit the synthesis of corticotrophin-releasing
hormone (CRH) mRNA, as well as activating the synthesis of
glucocorticoid receptor mRNA in the hippocampus. These
actions amount to a lowering of the activity level in a major
endocrine axis involved in stress responses. TCAs and other
ADs might thus act as “antistress” molecules. Amitriptyline
also increases luteinizing hormone–releasing hormone
(LHRH) mRNA. Taken together, these findings are of interest
since increased cortisol and decreased testosterone secretion
have been associated with severe depression. Few ADs have
been studied in this connection. Some findings are inconsis-
tent, in the sense that some clinically effective ADs do not
downregulate the axis leading to the secretion of cortisol.
Other compounds, such as interferon and the interleukins 
(IL-1, IL-6) are also interesting to study in relation to ADs,
because these substances can stimulate the hypothalamo-
hypophyseal-adrenocortical axis. Other sites of potential phar-
macological actions of ADs are the recently discovered anan-
damine, an endogenous ligand to the cannabis receptor. ADs
may also act on sigma receptors, glutamatergic systems
(glycine site on the N-methyl-D-aspartate [NMDA] receptor),
cholinergic systems, substance P, and neurotrophins. The data
on AD “enzymograms,” “receptorograms,” and “transportero-
grams” are extensive; they provide useful help in understanding
many of the clinical effects of ADs, but they are permanently
being updated, which makes the comparison between ADs on
the basis of their biochemical mode of action a difficult chal-
lenge. The multiple biochemical effects of ADs are still impos-
sible to integrate into a single explanation of their mode of
action. Current hypotheses suggest the existence of a common
final pathway for the monoamine and neuroendocrine systems
or a mechanism involving remodeling of defective synapses.
Pharmacokinetics
There are few differences in pharmacokinetics between ADs.
One major difference is the elimination half-life (T
1/2β ). For
example, venlafaxine has a very short half-life of only a cou-
ple of hours, while fluoxetine has a very long one of several
days. The clearance of ADs is decreased in patients over 70
years of age and in severe hepatic insufficiency. Renal insuf-
ficiency leads to high concentrations of the hydroxylated and
conjugated metabolites, but this has few proven clinical con-
sequences. Several ADs inhibit different cytochrome P450
enzymes, and this can lead to adverse drug reactions when
patients are receiving multiple drugs. Among the recent ADs,
citalopram, moclobemide, and sertraline induce little enzy-
matic inhibition of this type.
Influence of patient characteristics
Patient characteristics can modify the effects of ADs. These
differences are such that the same SSRI may be judged by
one patient as absolutely free of any adverse drug reaction,
while another patient will complain of a long list of adverse
reactions and will have to discontinue the medication. In
some cases, drug monitoring has shown that individual dif-
ferences in intensity of response to ADs are not obligatorily
of pharmacokinetic origin, in the sense that subjects with
AD concentrations in the lower ranges can show adverse
drug reactions, while subjects with concentrations in the
higher ranges have no complaints. There is little informa-
tion on the dose-response curves of psychotropic medica-
tions in individual patients. This means that, while we know
that the clearance of ADs can vary between patients by a
factor or up to 5 or more, we do not know the quantitative
range of variation of sensitivity to the beneficial or deleteri-
ous effects of ADs. It might be that some populations of
patients have very little chance of benefiting from treatment.
A situation of this type was identified in relation to the pre-
vention of myocardial infarction (relapse rate) 3 years after a
first infarction.
12 Overall, propranolol had a protective effect
of 3% (reinfarction rate of 12% with propranolol and 9%
with placebo). But the relapse rate was 6% in subjects with a
high educational level compared to 13% when this level was
low, and 2% in subjects with low stress and social isolation
compared to 14% when these were high. These findings in
the field of cardiology suggest that financial, social, or edu-
cational measures might be more effective than drug treat-
ment in disadvantaged patients groups. How this concept
applies to AD treatment is still unclear.
It is possible that the risk of developing psychiatric adverse
drug reactions is dependent on the patients more than the drugs
themselves. For example, hyperthymic personality might be an
independent risk factor for drug-induced hypomania. The rule
of baseline characteristics states that if a patient presents with
a preexisting physical abnormality before treatment, then the
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9risk of an iatrogenic reaction having the characteristics of
this abnormality is greatly increased. Thus, an elderly patient
with age-related cognitive decline will be more sensitive to
the amnestic effects of anticholinergics or benzodiazepines,
and a patient with orthostatic hypotension will be more sen-
sitive to the hypotensive effects of medications. With ADs, the
rule of baseline characteristics is probably predictive of a
greater risk for most adverse drug reactions. Interindividual
differences are the domain of pharmacogenetic studies, and
the hope is that better knowledge of genetic polymorphism
will facilitate the prediction of both the favorable and adverse
effects of drugs.
Cost of antidepressant therapy
Health care costs have long been a cause for concern and,
indeed, there is no room for euphoria when health care costs
are soaring to more than 10% of gross national products in
some Western countries. In 1978, the Palo Alto Times pub-
lished a cartoon in which Cicero was playing the part of a
doctor being asked by Bugs Bunny: “How sick am I doc?”
Cicero’s answer was: “That depends on how well you are
insured.” Health economists have conflicting interests; each
individual, each institution wishes to maximize its benefits
and minimize its losses, with little consideration for the
health and well-being of the nation as a whole. In Switzer-
land, a well-known insurance company gave a regrettable
confirmation of this sad state of affairs when they stopped
providing the basic mandatory insurance package in Swiss
cantons where health expenditure was judged to be too high.
The American public holds the belief that “managed care
has killed patient care.” Yet nobody would like to see renal
transplants or access to intensive care units being denied to
citizens above 65 years of age, as tended to be the case 25
years ago in Geneva. 
Coming back to the costs of AD therapy, as only a small pro-
portion of patients with ARDs are currently being treated,
their number stands to increase, and costs, therefore, like-
wise. If we look at the pharmacoeconomics of ADs, it is obvi-
ous that the older ADs are less costly, ie, a dosage of 2 tablets
a day of a recent AD can cost more than twice the price of 150
mg per day of a TCA(incidentally, the average $200 cost for
100 tablets of the recent ADs is equivalent to the monthly
salary of a psychiatrist in many countries from the former
Soviet Union bloc). This high price of the newer ADs raises
the issue of the comparison of the costs of pharmacotherapy
and psychotherapy. In Switzerland, the cost of a twice-daily
dosage of tablets of the newer ADs is a quarter to a third of a
weekly psychotherapy session with a psychiatrist, and half the
cost of a weekly session with a psychologist. 
Despite the fact that the newer ADs are more expensive,
pharmacoeconomic analysis shows them to be advanta-
geous.
13 This conclusion is based on the fact that these drugs
are associated with a smaller number of accidents, that
adverse reactions caused by them necessitate fewer medical
interventions (as opposed, for example, to TCAs, which can
lead to urinary obstruction requiring urinary catheterization,
with the risk of secondary infection). The global cost of ARD
therapy is therefore in the recent ADs' favor, but the margin
of this advantage is small, in the range of 5% and rarely
more than 20%, depending on the models chosen for the cal-
culation.
Conclusion
No AD seems to be significantly superior to any other in
terms of clinical efficacy. All have a delayed onset of benefi-
cial effects, and all influence indolamines or catecholamines
in one way or another. However, the differences between
ADs outnumber their similarities, and this has implications for
the choice of treatment. We recommend prescribing the recent
ADs as first-line treatment, and that TCAs should be given
only in the event of treatment resistance. We recommend bas-
ing therapeutic choices on the “disorderogram,” the configu-
ration of adverse drug reactions, and the configuration of
pharmacological actions (“receptorogram,” “enzymogram,”
“transporterogram”). These pharmacological data are con-
stantly being updated by new findings, but they provide a
useful basis for the choice of compounds that will provide
clinical efficacy against ARDs. ❏
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¿ Son  iguales todos los antidepresivos ?
Existen alrededor de 40 trastornos en los que se pre-
scriben antidepresivos, entre los cuales se incluyen los
trastornos afectivos, trastornos ansiosos, y otros. Pro-
ponemos llamarlos « trastornos que responden a anti-
depresivos » (antidepressant-responsive disorders,
ARDs)  Se describen los criterios clínicos y biológicos
que diferencian los antidepresivos.A pesar de que en
la mayoría de los ARDs los antidepresivos comparten
la misma eficacia clínica, la configuración y las reac-
ciones adversas de cada fármaco varían ampliamente.
Se debería preferir  los antidepresivos recientes a los
antidepresivos tricíclicos en la prescripción de un
tratamiento de primera elección, dado que presentan
un riesgo menor de reacciones adversas. Sin embargo,
varios antidepresivos recientes han sido relacionados
con complicaciones severas tales como el síndrome
serotoninérgico y el síndrome de abstinencia. Deben
incluirse las características del paciente como criterio
de predicción tanto de los efectos indeseables como
beneficiosos.
Les antidépresseurs sont-ils tous pareils ?
Les antidépresseurs sont indiqués dans environ une
quarantaine de troubles différents, tels les troubles de
l'humeur, les troubles anxieux, etc. Pour désigner
l'ensemble de ces troubles, nous proposons l'appella-
tion « antidepressant-responsive disorders »,soit « trou-
bles répondant à l'action des antidépresseurs ». Dans
cet article sont énoncés les critères cliniques et
biologiques permettant de différencier les antidé-
presseurs. Alors que l'efficacité de ces médicaments
dans les différents troubles évoqués ci-dessus est
grossièrement identique, tel n'est pas le cas de leurs
profils d'effets indésirables où des différences notables
existent. La famille des tricycliques doit désormais
céder la place aux antidépresseurs récents pour ce qui
concerne le traitement de première intention eu égard à
la plus faible incidence des effets indésirables rencon-
trés avec ces derniers.Cependant,il faut noter que cer-
tains antidépresseurs récents ont pu être associés à des
complications graves du type syndrome sérotonin-
ergique ou syndrome de sevrage. Les caractéristiques
des patients jouent également un rôle essentiel pour
prédire les effets aussi bien bénéfiques qu'indésirables
liés à l'utilisation des antidépresseurs.
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